Denmark-based clinical-stage biotech company NMD Pharma A/S announced on Tuesday that it has secured US Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application to initiate a Phase 2 trial (SYNAPSE-CMT) of NMD670, a first-in-class muscle-targeted therapy, in patients with Charcot-Marie-Tooth (CMT) type 1 and 2.
The randomised, double-blind, placebo-controlled trial will assess the safety, efficacy and tolerability of NMD670 in around 80 adult patients across the United States and Europe. Expected to begin enrolment soon, the 21-day trial will evaluate endpoints including 6-minute walk test and timed-up-and-go test.
This follows NMD Pharma's announcement of positive results from the ESTABLISH study in June 2023, highlighting neuromuscular junction dysfunction as a characteristic in CMT patients.
SYNAPSE-CMT joins two ongoing Phase 2 trials of NMD670 for spinal muscular atrophy (SMA) type 3 and generalised myasthenia gravis, solidifying NMD Pharma's focus on rare neuromuscular diseases.
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
AstraZeneca's Wainzua recommended for EU approval
Astellas Pharma's VYLOY receives US FDA approval
Accord Healthcare wins CHMP approval for Stelara biosimilar Imuldosa
Ionis and AstraZeneca's WAINZUA recommended for EU approval
Novartis receives positive CHMP opinion for Kisqali
Viatris signs exclusive licensing agreement with Lexicon Pharmaceuticals
Adicet Bio receives FDA clearance to expand ADI-001 trials to additional autoimmune diseases
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
SystImmune receives FDA clearance for Phase 1 trial of novel AML therapy
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
PTC Therapeutics' sepiapterin receives US FDA target regulatory action date
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA